EFFORTIL (Etilefrine) - (Low-flow priapism)

Opinions on drugs - Posted on Oct 16 2024

Reason for request

First listing

Summary of opinion

Unfavourable opinion for reimbursement in “the treatment of low-flow priapism in adults, particularly in sickle cell disease, and in the secondary prevention of low-flow priapism in adults and children over 2 years of age (solution in drops) or 6 years of age (tablets), particularly in sickle cell disease.”

Clinical Benefit

Insufficient

The Committee deems that the clinical benefit of oral EFFORTIL (etilefrine) is insufficient in the MA indications to justify public funding in view of the available alternatives.